Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 1801 AL 1815

Design and Synthesis of Dopaminergic Agonists

Matute MS, Matute R, Merino P.

Curr Med Chem. 2016;23(25):2790-2825. doi: 10.2174/0929867323666160504103621.

Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease

Grow DA, McCarrey JR, Navara CS.

Stem Cell Res. 2016 Sep;17(2):352-366. doi: 10.1016/j.scr.2016.08.013. Epub 2016 Aug 26.

microRNAs involved in Parkinson's disease: A systematic review

da Silva FC, Iop RD, Vietta GG, Kair DA, Gutierres Filho PJ, de Alvarenga JG, da Silva R.

Mol Med Rep. 2016 Nov;14(5):4015-4022. doi: 10.3892/mmr.2016.5759. Epub 2016 Sep 22.

Severe Parkinsonism with respiratory failure in peritoneal dialysis patient

Gallegos-Villalobos A, Ruiz-Criado J, Rodríguez A, Fernandez-Rodríguez F, Gascón A.

Nefrologia. 2016 Nov-Dec;36(6):721-722. doi: 10.1016/j.nefro.2016.09.003. Epub 2016 Sep 30.

Novel Levodopa Formulations for Parkinson's Disease

Freitas ME, Ruiz-Lopez M, Fox SH.

CNS Drugs. 2016 Nov;30(11):1079-1095. doi: 10.1007/s40263-016-0386-8.

An Update on the Role of Nitric Oxide in the Neurodegenerative Processes of Parkinson's Disease

Jiménez-Jiménez FJ, Alonso-Navarro H, Herrero MT, García-Martín E, Agúndez JA.

Curr Med Chem. 2016;23(24):2666-2679. doi: 10.2174/0929867323666160812151356.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era

Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE.

Trends Neurosci. 2016 Nov;39(11):750-762. doi: 10.1016/j.tins.2016.09.003. Epub 2016 Oct 21.

[Advances in the association of ATP-sensitive potassium channels and Parkinson's disease]

DU XX, Qin K, Jiao Q, Xie JX, Jiang H.

Sheng Li Xue Bao. 2016 Oct 25;68(5):644-648.

[Brain asymmetry and dopamine: beyond motor implications in Parkinson's disease and experimental hemiparkinsonism]

Segarra AB, Banegas I, Prieto I, Ramirez-Sanchez M.

Rev Neurol. 2016 Nov 1;63(9):415-421.

A meta-analysis of the pedunculopontine nucleus deep-brain stimulation effects on Parkinson's disease

Wang H, Gao H, Jiao T, Luo Z.

Neuroreport. 2016 Dec 14;27(18):1336-1344. doi: 10.1097/WNR.0000000000000697.

Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management

Tinazzi M, Geroin C, Gandolfi M, Smania N, Tamburin S, Morgante F, Fasano A.

Mov Disord. 2016 Dec;31(12):1785-1795. doi: 10.1002/mds.26829. Epub 2016 Oct 25.

Psychometric Properties of a Generic, Patient-Centred Palliative Care Outcome Measure of Symptom Burden for People with Progressive Long Term Neurological Conditions

Gao W, Crosby V, Wilcock A, Burman R, Silber E, Hepgul N, Chaudhuri KR, Higginson IJ; OPTCARE Neuro trial.

PLoS One. 2016 Oct 25;11(10):e0165379. doi: 10.1371/journal.pone.0165379. eCollection 2016.

Visual signs and symptoms of corticobasal degeneration

Armstrong RA.

Clin Exp Optom. 2016 Nov;99(6):498-506. doi: 10.1111/cxo.12429. Epub 2016 Aug 23.

Reviewing the Evidence: In Pursuit of a Framework for Parkinson Disease Rehabilitation with Games

Tece Bayrak A, Wünsche B, Lutteroth C.

Stud Health Technol Inform. 2016;231:9-17.

Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration

Perez-Lloret S, Peralta MC, Barrantes FJ.

Expert Opin Pharmacother. 2016 Dec;17(18):2405-2415. doi: 10.1080/14656566.2016.1254189. Epub 2016 Nov 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias